In solid tumors, B7 homolog 3 protein (B7-H3) transmembrane protein [68], also known as CD276, is an emerging immunotherapy target, particularly appealing for its overexpression in multiple solid tumor types, including hepatocellular carcinoma (HCC), lung adenocarcinoma (LUAD), and neuroblastoma (NB) [69], while mostly absent in healthy patients. This evidence concerns the gene CD276 and neuroblastoma.